Author: Alkhouri, Naim; Kohli, Anita; Loomba, Rohit; Harrison, Stephen A.
Title: Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARSâ€CoVâ€2 Pandemic Cord-id: ahiztg7f Document date: 2020_8_14
ID: ahiztg7f
Snippet: Coronavirus disease 2019 (COVIDâ€19), the illness caused by the SARSâ€CoVâ€2 virus, has spread rapidly throughout the world overwhelming healthcare systems. Fever and cough are the dominant symptoms with 15% of patients developing severe illness especially in the elderly and those with concurrent illnesses. Quarantine, shelter in place, and social distancing strategies have been instituted, restricting people from going out for all but essential services. The prevalence of nonalcoholic fatty
Document: Coronavirus disease 2019 (COVIDâ€19), the illness caused by the SARSâ€CoVâ€2 virus, has spread rapidly throughout the world overwhelming healthcare systems. Fever and cough are the dominant symptoms with 15% of patients developing severe illness especially in the elderly and those with concurrent illnesses. Quarantine, shelter in place, and social distancing strategies have been instituted, restricting people from going out for all but essential services. The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), have steadily increased and now affect approximately 25% of the global population.
Search related documents:
Co phrase search for related documents- additional risk and liver injury: 1
- liver disease and local laboratory: 1
Co phrase search for related documents, hyperlinks ordered by date